PeppiLibrary

Cognitive

Cerebrolysin peptide reference

Porcine brain-derived peptide mixture. Approved abroad for stroke and dementia.

Last reviewed May 6, 2026 Human data Not FDA approved
Peppi reviewing Cerebrolysin notes
Default dose labelNot listed
Preferred routeIM (clinical) or IV
Frequency labelDaily during course
Storage windowNot listed

Evidence snapshot

Human data

Evidence maturityHuman data
Approved in 50+ countries with multiple Phase 3 trials; not FDA-approved

Prescription medication abroad; not approved in US/UK

Route map

How records are usually labeled

1 IM
2 IV
3 SubQ (off-label)

Rotate IM sites for daily dosing.

Vial timeline

Storage cues to log

Before mixRoom temperature; protect from light.
After mixN/A — pre-formulated, single-use ampoule.
Use-by cueShelf life not listed
Mixed vial windowNot listed
Use this as a record-keeping cue, not a replacement for product labeling.

Peppi workflow

From vial to review

Vial label
Dose Not listed
Route IM (clinical) or IV
Review storage

Peppi turns scattered dose, vial, route, storage, note, and report details into one record trail.

Educational reference only

This page helps you understand what to track for Cerebrolysin. It is not medical advice, a prescription, or a recommendation to use this peptide. Discuss dose, route, timing, storage, and safety with a qualified healthcare professional.

Overview

Cerebrolysin is not a single peptide but a standardised mixture of low-molecular-weight peptides and amino acids derived from purified porcine brain proteins via enzymatic breakdown. It mimics the action of endogenous neurotrophic factors. Approved in 50+ countries for stroke, traumatic brain injury, vascular dementia, and Alzheimer's disease — but not in the US, UK, or most Western markets.

Also known as: FPF-1070.

Acute ischaemic stroke (approved abroad)Traumatic brain injury (approved abroad)Vascular dementia and Alzheimer's (approved abroad)Cognitive support in neurodegenerative research

Mechanism and timing snapshot

Mimics endogenous neurotrophic factors (BDNF, NGF, GDNF). Promotes neuronal differentiation, neuroprotection against ischaemia, modulates microglial inflammation, and supports synaptic plasticity.

Onset labelNot listed
Catalog onset field, when available.
Half-life labelNot listed
Mixture pharmacokinetics — components have varying half-lives
Duration label24 hr
Catalog duration field, when available.
IM Standard administration route
IV Standard administration route
subQ Less common
oral Negligible

Tracking defaults

These values come from Peppi's catalog so records can be prefilled consistently. They should be reviewed against your clinician's instructions before logging real-world use.

Catalog default doseNot listed
Catalog dose rangeNot listed - Not listed
Default routeIM
Frequency labelDaily during course
Best time labelMorning, consistent timing.
Food noteNone.

Catalog protocol note

Stroke/dementia: 5–30 mL IM or IV daily for 10–20 days, repeated quarterly. (Dosing in mL of standardised solution, not mcg.)

Routes and site notes

Available route labelsIM, IV, SubQ (off-label)
Preferred route labelIM (clinical) or IV
Common site labelsGlute (IM), Vein (IV)
Site rotation noteRotate IM sites for daily dosing.

Chemistry

SequenceHeterogeneous mixture; ~25% peptides <10 kDa, ~75% free amino acids
Amino acidsNot listed
Molecular formulaNot listed
Molecular weightNot listed

Vial, reconstitution, and storage

Supply formPre-formulated solution in ampoules (1, 5, 10, 30 mL sizes)
Typical vial sizeNot listed
DiluentN/A — pre-formulated
Diluent volumeNot listed
Concentration noteStandard concentration 215.2 mg peptide/amino-acid mixture per mL solution.
Before reconstitutionRoom temperature; protect from light.
After reconstitutionN/A — pre-formulated, single-use ampoule.
Reconstituted shelf lifeNot listed
Light sensitiveYes
Freeze/thaw warningNo

Safety notes

Common and rare side effects listed in the catalog

  • Injection-site reactions
  • Mild fever
  • Sensation of warmth
  • Headache
  • Allergic reactions
  • Seizure threshold lowering (caution in epilepsy)

Contraindications and warnings

  • Severe renal impairment
  • Status epilepticus
  • Pregnancy
  • Not FDA-approved in US.
  • Porcine origin — verify acceptability for religious or dietary preferences.

Other considerations

  • Mixture pharmacology — quality and consistency depend heavily on manufacturer.
  • Course-based dosing (10–20 days, then break) is standard.
  • Most clinical evidence comes from Eastern European and Russian trials.

Evidence and regulatory context

Evidence levelApproved in 50+ countries with multiple Phase 3 trials; not FDA-approved
FDA approvedNo
Regulatory statusPrescription medication abroad; not approved in US/UK
Prescription requiredYes
Approved countriesRussia, China, Austria, Germany, and 50+ others

Stacking and cycle notes

Stacks well withNot listed
Avoid combining noteMAOIs
Typical cycle label2–3 (course)
Typical break label12 (3 months)
Cycle guidanceQuarterly courses are typical. Continuous daily use is not the protocol.

Tracking tips

  • Course-based dosing — daily for 2–3 weeks, then off for 3 months.
  • Porcine-derived — verify acceptability for dietary/religious considerations.
  • Quality varies between manufacturers; the EVER Pharma branded product has the strongest evidence base.

References

Track it in Peppi

Keep Cerebrolysin records organized.

Use Peppi for dose logs, vial inventory, storage dates, reminders, journal notes, photos, and clinician-ready reports.

Download on theApp Store Get it onGoogle Play

FAQ

What should I track for Cerebrolysin?

Track the peptide name, dose amount and unit, route, vial label, timing, reconstitution or expiration dates, storage notes, and any symptoms or questions for clinician review.

Does Peppi tell me how to use Cerebrolysin?

No. Peppi organizes educational reference and your own records. Protocol decisions should come from a qualified healthcare professional.

Can I export Cerebrolysin records?

Peppi is designed to keep dose logs, vial inventory, journal notes, and reports easier to review and export.

Last reviewed: May 6, 2026